23 May 2013
Keywords: qlt, 6-month, eligard, cleared, eu, canadian, drugmaker
Article | 10 September 2007
Canadian drugmaker QLT's prostate cancer drug Eligard (leuprolide) has been approved in the European Union in a 45mg six-month formulation. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 November 2007
7 May 2007
22 May 2013
© 2013 thepharmaletter.com